Abstract:Fundamentally, cancer arises from genetic and epigenetic alterations that interplay to reprogram gene expression networks, leading to unrestrained proliferation. Glioblastoma (GBM) is the most prevalent and aggressive primary brain cancer, with a median survival of approximately one year and a 5-year survival rate of just 5%. The standard care for GBM patients has remained unchanged for decades, underscoring the need for a better understanding of GBM biology to develop more effective therapies. The relatively low genetic mutation burden in GBM highlights the significant role of epigenetic mechanisms in its pathogenesis. Our recent work shows that chromatin remodeling plays pivotal roles in GBM pathogenesis. The BRD8-driven EP400 chromatin remodeling complex maintains GBM by crippling p53-mediated tumor suppression in an unprecedented way through hijacking the histone variant H2AZ at p53 target loci, enforcing a repressive chromatin state that prevents p53-mediated transactivation. Targeting BRD8 in TP53 WT GBM, which makes up ~71% of all GBM cases, enhances chromatin accessibility by evicting H2AZ. This restores p53-mediated transactivation of its targets, reestablishes cell cycle arrest, inhibits gliomagenesis, and prolongs survival in xenograft models of TP53 WT GBM. Conversely, the NuRD chromatin remodeling complex driven by CHD5 governs the MYC-mediated oncogenic network to prevent gliomagenesis. Mechanistically, CHD5 forms a CHD3-containing but CHD4-independent NuRD complex that directly binds to the MYC promoter and super enhancers. Chd5 loss triggers the remodeling of chromatin, enhances chromatin accessibility at Myc loci, augments Myc expression, significantly impairs NSCs differentiation while promotes proliferation, transformation, and gliomagenesis in vivo . Furthermore, reactivating CHD5 in human GBM xenograft models significantly extends survival. Thus, our findings reveal previously unappreciated epigenetic mechanisms by which GBM cells reprogram both tumor-suppressive and oncogenic transcription networks to facilitate their outgrowth. This sheds new light on our understanding of GBM malignancy and provides promising therapeutic opportunities for treating patients with this devastating malignancy.

PHF20 Promotes Glioblastoma Cell Malignancies Through a WISP1/BGN-Dependent Pathway

Hmga2 Sustains Self-Renewal and Invasiveness of Glioma-Initiating Cells

Dual Role of WISP1 in Maintaining Glioma Stem Cells and Tumor-Supportive Macrophages in Glioblastoma

PHF20 Collaborates with PARP1 to Promote Stemness and Aggressiveness of Neuroblastoma Cells Through Activation of SOX2 and OCT4

Silencing Expression of PHF14 in Glioblastoma Promotes Apoptosis, Mitigates Proliferation and Invasiveness Via Wnt Signal Pathway

HSP47 Promotes Glioblastoma Stemlike Cell Survival by Modulating Tumor Microenvironment Extracellular Matrix Through TGF-β Pathway.

Identification of Wisp1 As A Novel Oncogene in Glioblastoma

Activation of JNK and P38 MAPK Mediated by ZDHHC17 Drives Glioblastoma Multiforme Development and Malignant Progression.

PPFIBP1 induces glioma cell migration and invasion through FAK/Src/JNK signaling pathway

Hypoxia-induced TGFBI maintains glioma stem cells by stabilizing EphA2

KIF15 promotes human glioblastoma progression under the synergistic transactivation of REST and P300

Epco-27. Chromatin Remodeling Reprograms The Transcription Network In Glioblastoma

ISL1 Promotes Human Glioblastoma-Derived Stem Cells' Self-Renewal by Activation of Sonic Hedgehog/GLI1 Function.

Nestin<SUP>+</SUP>/CD31<SUP>+</SUP> cells in the hypoxic perivascular niche regulate glioblastoma chemoresistance by upregulating JAG1 and DLL4

PDCD10-Deficiency Promotes Malignant Behaviors and Tumor Growth Via Triggering EphB4 Kinase Activity in Glioblastoma.

Identification of PDLIM1 as a glioblastoma stem cell marker driving tumorigenesis and chemoresistance

ZBTB20 suppresses tumor growth in glioblastoma through activating the TET1/FAS/caspase‐3 pathway

Induction of cancer cell stemness in glioma through glycolysis and the long noncoding RNA HULC-activated FOXM1/AGR2/HIF-1α axis

HOXA5 is amplified in glioblastoma stem cells and promotes tumor progression by transcriptionally activating PTPRZ1

LEF1 Regulates Glioblastoma Cell Proliferation, Migration, Invasion, and Cancer Stem-Like Cell Self-Renewal

FGD5-AS1 Facilitates Glioblastoma Progression by Activation of Wnt/β-catenin Signaling Via Regulating Mir-129-5p/hnrnpk Axis